Compare Becton Dickinson and Co (BDX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Weibo Corp — how do they compare? Becton Dickinson and Co trades at $156.19 (market cap $41.51B), while Weibo Corp trades at $7.83 (market cap $1.88B). The key difference: Becton Dickinson and Co is far larger — about 22.1× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.96%). Which is the better fit depends on your goals.
| BDX | WB | |
|---|---|---|
Market Cap | $41.51B | $1.88B |
Sector | Health | Media |
52-Week High | $185.39 | $12.83 |
52-Week Low | $135.49 | $7.20 |
Enterprise Value | $57.97B | $1.16B |
Dividend Yield | 2.79% | 7.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Weibo (WB) trades at $7.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong valuation metrics including a P/E of 5.37 and P/B of 0.49. The company reported $449.02M net income for 2025 with a 25.55% margin, though recent quarters saw EPS misses. A $0.61 dividend for H1-26 is scheduled, and cash flow trends show improvement in 2025. Analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. Upside is supported by low multiples and robust cash flow, but risks include user engagement challenges from rivals like Douyin and inconsistent earnings performance. The stock presents a value opportunity with income, yet requires monitoring of competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
